Brief: Tempest Presents Data Showing Tpst-1120-Induced Pharmacodynamic Changes Consistent With Clinical Benefit Observed In Patients With Cancer
10/11/2022 16:27
Nov 10 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST PRESENTS DATA SHOWING TPST-1120-INDUCED
PHARMACODYNAMIC
CHANGES CONSISTENT WITH CLINICAL BENEFIT OBSERVED IN PATIENTS
WITH CANCER
Source text for Eikon: ID:nGNXbNnZ24
Further company coverage: TPST.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T